Technology ID
TAB-4481

Compositions and Methods for Reducing Serum Triglycerides

E-Numbers
E-054-2019-0
Lead Inventor
Fowler, Alexandra
Lead IC
NHLBI
Co-Inventors
Remaley, Alan
Amar, Marcelo
Chackerian, Bryce
ICs
NHLBI
Applications
Vaccines­­­
Therapeutics
Research Materials
Therapeutic Areas
Cardiology
Development Stages
Pre-clinical (in vivo)

This technology includes a vaccine for lowering plasma triglycerides by inducing the formation of autoantibodies against either ANGPTL3 or ANGPTL4, which are inhibitors of Lipoprotein Lipase. This was done by conjugating synthetic peptides based on ANGPTL3 or ANGPTL4 to virus- like particles (VLPS). Injection of the vaccine in animal models was shown to induce the autoantibody against the target and to lower plasma triglycerides.

Commercial Applications
Development into a novel therapy for lowering plasma triglycerides.

Competitive Advantages
The vaccine strategy for lowering plasma triglycerides is novel and could represent a low-cost alternative to drug therapy.

Request More Info

Licensing Contact:
Davis, Michael
nihott@nih.gov

Collaborations

  • Licensing

Collaboration Description

  • We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology.
Date Published